ARCHIVES

ODAC votes 9-6 in favor of Clolar for pediatric acute lymphoblastic leukemia, but votes against Marqibo for non-Hodgkin’s lymphoma.

This article is from The Cancer Letter archive.

Vol. 30 No. 46 | December 10, 2004

Download PDF Visit The Full Archive

Related Articles

Alimta Granted Approval As NSCLC Continuation Therapy

November 25, 2011

Cooperative Groups With Cancer Control Contracts Receive Two Year Renewals

March 25, 1983

DCPC Advisors Request New Study Section In Prevention And Control Of Chronic Disease

July 30, 1993

Two cancer center directors named: Michael Kastan at St. Jude, James Willson at Harold Simmons.

December 10, 2004

Oxaliplatin Regimen May Beat Standard For Advanced Colorectal Cancer, NCI Says

April 26, 2002

Niccotine Reports As Aiding Metastasis

August 22, 1986